deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02066285

Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma

A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)

Sponsor: Grupo Espanol de Investigacion en Sarcomas

Conditions Extraskeletal Myxoid Chondrosarcoma Solitary Fibrous Tumor
Interventions Pazopanib
Updated 12 times since 2017 Last updated: Mar 24, 2023 Started: Jun 30, 2014 Primary completion: Dec 31, 2019 Completion: Mar 24, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02066285, this PHASE2 trial focuses on Extraskeletal Myxoid Chondrosarcoma and Solitary Fibrous Tumor and remains completed. Sponsored by Grupo Espanol de Investigacion en Sarcomas, it has been updated 12 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotRecruiting~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotRecruiting~Jul 2018 – ~Oct 2019 · 15 months · monthly snapshotUnknown Status~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshotActive Not Recruiting~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotActive Not Recruiting~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshotActive Not Recruiting~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshotActive Not Recruiting~Feb 2022 – ~Apr 2023 · 14 months · monthly snapshotActive Not Recruiting~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 12 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Apr 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Feb 2022 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 7 earlier versions

  1. Sep 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

  4. Oct 2019 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Unknown Status → Active Not Recruiting

  5. Jul 2018 — Oct 2019 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  6. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  7. Jan 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Grupo Espanol de Investigacion en Sarcomas
Data source: Grupo Espanol de Investigacion en Sarcomas

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations